Scientists designed and developed a novel 2+1 EGFRvIII-TCB with optimal pharmacological characteristics and potent anti-tumor activity.
[Molecular Cancer Therapeutics]
Home Newsletters Immune Regulation News A Novel EGFRvIII-T Cell Bispecific Antibody for the Treatment of Glioblastoma
